Activation of the transcription factor AP-1 (activator protein-1) is required for tumor promotion and maintenance of malignant phenotype. A number of AP-1-regulated genes that play a role in tumor progression have been identified. However, AP-1-regulated genes driving tumor induction are yet to be defined. Previous studies have established that expression of a dominant-negative c-Jun (TAM67) inhibits phorbol 12-tetradecanoyl-13-acetate (TPA)-induced AP-1 transactivation as well as transformation in mouse epidermal JB6/P þ cells and tumor promotion in mouse skin carcinogenesis. In this study, we utilized the tumor promotion-sensitive JB6/P þ cells to identify AP-1-regulated TAM67 target genes and to establish causal significance in transformation for one target gene. A 2700 cDNA microarray was queried with RNA from TPA-treated P þ cells with or without TAM67 expression. Under conditions in which TAM expression inhibited TPA-induced transformation, microarray analysis identified a subset of six genes induced by TPA and suppressed by TAM67. One of the identified genes, the high-mobility group protein A1 (Hmga1) is induced by TPA in P þ , but not in transformationresistant P cells. We show that TPA induction of the architectural transcription factor HMGA1 is inhibited by TAM67, is extracellular-signal-regulated kinase (ERK)-activation dependent, and is mediated by AP-1. HMGA1 antisense construct transfected into P þ cells blocked HMGA1 protein expression and inhibited TPA-induced transformation indicating that HMGA1 is required for transformation. HMGA1 is not however sufficient as HMGA1a or HMGA1b overexpression did not confer transformation sensitivity on PÀ cells. Although HMGA1 expression is ERK dependent, it is not the only ERKdependent event required for transformation because it does not suffice to rescue ERK-deficient PÀ cells. Our study shows (a) TAM 67 when it inhibits AP-1 and transformation, targets a relatively small number of genes; (b) HMGA1, a TAM67 target gene, is causally related to transformation and therefore a potentially important target for cancer prevention.
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Introduction
Carcinogenesis is a multistage process that involves transformation of cells to a preinvasive lesion and ultimately to a cancer that invades into surrounding tissues and produces distant metastases. Carcinogenesis is caused by mutations and gene regulation events that activate proto-oncogenes and inactivate tumor suppressor genes (Hanahan and Weinberg, 2000; Balmain, 2001) . Rate-limiting events occur during tumor promotion and tumor progression. Some of these rate-limiting events occur during signal transduction from membrane receptors through kinase cascades to regulators of transcription or translation. The transcription factor activator protein 1 (AP-1) (Angel and Karin, 1991) is important in driving tumorigenesis in many disease sites in mice and humans .
The AP-1 transcription factor consists of a dimer containing Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra-1, Fra-2) proteins. Dimerization through a leucine zipper domain is necessary for binding to AP-1 sites on gene promoters. The transactivation domains of Jun and Fos proteins are activated by phosphorylation in response to extracellular stimuli such as growth factors, cytokines, stress and UV light (Angel and Karin, 1991; Karin et al., 1997; van Dam and Castellazzi, 2001) . A transactivation domain deletion mutant of c-Jun (TAM67) has a dominant-negative effect on AP-1-dependent transcription. The dominantnegative effect of TAM67 arises from its ability to form dimers with wild-type AP-1 proteins that are rendered low-activity by harboring a single transactivation domain (Brown et al., 1993) . Although basal levels of AP-1 activity are needed for normal function, elevated levels can drive tumor progression and contribute to maintaining tumor phenotype (Jochum et al., 2001; Shaulian and Karin, 2001 ). Studies using subtractive hybridization or differential display have identified AP-1-regulated genes that contribute to invasion or metastasis. Among these AP-1 target genes are matrix metalloproteinases and adhesion-related genes Ozanne et al., 2000; Reeves et al., 2001) . Much less is known of AP-1 target genes that are important in tumor promotion, an earlier stage that yields preinvasive lesions.
The JB6 mouse epidermal cell model has been valuable in identifying AP-1, NF-kB and other signaling or transcription-related molecular events that are required for tumor promotion (Kovacic and Jacintho, 2001 ). The JB6 model consists of clonal variants that are transformation sensitive (P þ ) or resistant (PÀ) (Colburn et al., 1979; Colburn et al., 1981; Colburn et al., 1982; Bernstein and Colburn, 1989) . On treatment with tumor promoters such as EGF, TPA or TNFa, the P þ cells undergo transformation to tumor phenotype as manifested by anchorage-independent growth in softagar and tumorigenicity on mouse xenograft (Colburn et al., 1979; Colburn et al., 1982) . The PÀ cells do not show a transformation response to tumor promoters. Among the major mediators of the transformationsensitive phenotype of P þ cells are the extracellular signal-regulated kinase (ERK)/AP-1 and NF-kB pathways (Bernstein and Colburn, 1989; Bernstein et al., 1992; Bernstein et al., 1994; Frost et al., 1994; Huang et al., 1998; Watts et al., 1998; Huang et al., 1999; Hsu et al., 2001; Young et al., 2002b) . The level of ERK expression is especially critical for the transformation response in P þ cells, and reconstituting ERK expression in transformation-resistant PÀ cells confers transformation sensitivity to tumor promoters .
Expression of TAM67 in the P þ cells blocks TPA-induced AP-1 activity and transformation response (Dong et al., 1994) . This model has been predictive of in vivo tumor promotion effects. Transgenic mice expressing TAM67 in the skin are protected from the effects of 9,10-dimethyl-1,2-benzanthracene (DMBA)-initiated and TPA-promoted carcinogenesis (Young et al., 1999) while showing no inhibition of growth or hyperplasia. The goal of the present study was to demonstrate a TAM67 target gene that is functionally significant in transformation. Using microarray analysis, we identified a set of six genes whose expression was induced by TPA treatment and blocked by TAM67 expression in the presence of TPA. Of the six genes identified, the architectural transcription factor Hmga1 is induced by TPA in transformation-sensitive P þ cells, but not in PÀ cells (Cmarik et al., 1998) . The mouse and human HMGA1 promoters have sequence similarity including conserved AP-1 and AP-1-like sites (Pedulla et al., 2001 ). The human promoter, which is also TPA inducible, binds AP-1 proteins (Friedmann et al., 1993; Ogram and Reeves, 1995) . We therefore investigated the role of TPA-induced AP-1 in HMGA1 expression and the role of HMGA1 in the tumor promoter-induced transformation response in P þ cells.
The HMGA group of nonhistone chromatin proteins consists of HMGA1a (HMG-I), HMGA1b (HMG-Y) and HMGA2 (HMG-I/C) that are architectural transcription factors that bind to the AT-rich region in the minor groove of DNA. The same gene (HMGA1 in humans and Hmga1 in rodents) encodes for the HMGA1a and HMGA1b protein isoforms, which are derived by alternate splicing of the same mRNA and differ by 11 amino acids (Bustin and Reeves, 1996; Reeves et al., 2001) . Although not site-specific transcription factors, they exert positive and negative control over gene transcription by changing DNA folding and recruiting other transcription-related factors (Thanos and Maniatis, 1995) . The Rel (NF-kB) and Jun family are among the many transcription factors that interact with HMGA1 in controlling gene expression (Lewis et al., 1994; Chin et al., 1998; Himes et al., 2000; Bouallaga et al., 2003) . Elevated HMGA1 expression is commonly associated with malignant tumors, especially those with metastatic potential from a number of organs (Ram et al., 1993; Tamimi et al., 1993; Chiappetta et al., 1995; Abe et al., 1999) . While the association of HMGA1 with tumor phenotype is established, the role of these proteins in tumor promotion is not known.
In the present study, expression of an antisense HMGA1 construct in P þ cells suppressed the tumor promoter-induced transformation response, while expression of HMGA1a or HMGA1b protein in PÀ cells did not confer a gain in transformation response. TPA-induced HMGA1 expression in P þ cells is ERK -dependent, and transcription from the HMGA1 promoter is TAM67 sensitive. The results indicate that HMGA1 is necessary to drive tumor promoter-induced transformation response in ERKsufficient, AP-1-responsive P þ cells, but is not sufficient to convert the ERK-deficient, AP-1-nonresponsive, transformation-resistant PÀ cells to a transformationresponsive phenotype.
Results
A limited number of genes are targets for downregulation by dominant-negative c-jun (TAM67) during inhibition of TPA-induced transformation in P þ cells In order to identify genes directly or indirectly regulated by AP-1 that play a critical role in the transformation response, we carried out comparative gene expression profiling in TPA-induced P þ cells with or without TAM67 expression. Previous studies have shown that in the tumor promotion-sensitive P þ cells, TPA-induced transformation response is inhibited by the expression of TAM67 (Dong et al., 1994) . Under transformation inhibiting conditions, basal and TPA-induced AP-1 activity is also inhibited by the expression of TAM67 (Figure 1 ). While TPA induction occurred in the presence of TAM67, the level of TPA-induced AP-1 activity was reduced by approximately 65%. Transgenic mice expressing TAM67 and inhibited for tumorigenesis showed a similar 60-80% reduction of TPA-induced AP-1 level while retaining a fold-induction (Young et al., 1999; Young et al., 2002a; Cooper et al., 2003) . This degree of reduction suffices to drive AP-1 activity below the threshold level required for transformation, as has been determined by Suzukawa et al. (2002) .
To study the differences in gene expression profile in the absence and presence of TAM67, labeled cDNAs reverse transcribed from mRNA obtained from TPAtreated P þ and P þ /TAM67 cell lines were used to query a 2688 (2.7 k) cDNA microarray. The 2.7 k arrays were a designated NCI oncochip consisting of cDNA fragments representing numerous genes that are well characterized for their role in cancer. The mRNA was collected from cells treated with TPA or dimethyl sulfoxide (DMSO) for 6 and 18 h. Hybridization of labeled cDNAs in paired sets (TAM67 expressing versus vector control, for the same time point and TPA treatment status) was used to analyse change in gene expression. We sought to identify TPA-inducible genes that were suppressed by TAM67. Criteria used to determine genes with significant change in TPA-induced expression in the presence of TAM67 were: (1) genes downregulated by TAM67 expression in the presence of TPA had to be inducible by TPA treatment in the absence of TAM67; and, (2) for each gene, a minimum of two-fold change in expression with TPA induction and two-fold suppression by TAM67 in the presence of TPA, at a minimum of one time point. All experiments were performed twice and the values represent an average of the two independent experiments whose ranges varied by not more than 20% from the mean. The lack of TAM67 effects on proliferation or survival (Young et al., 1999) coupled with the double selection (TPA induced and TAM67 inhibited) increased the likelihood of 'capturing' genes functionally significant in transformation. That is, the experimental design and the biology of the model subtracts out irrelevant genes, thus leading to the expectation of identifying a relatively small set of genes enriched for those functionally significant in transformation.
In P þ cells treated with TPA compared with untreated control, of all genes that met quality control criteria (i.e. above a minimal expression level and 1.7-fold changed) in two independent experiments, 12 genes were upregulated and 7 genes were downregulated at both time points (6 and 18 h), while several other genes showed less sustained effects with up-or downregulation at one of the two time points. In experiments comparing gene expression in TPA-treated P þ /TAM67 versus P þ cells, six genes were downregulated twofold or more at one or both time points in independent experiments ( Figure 2a ). All of these six genes were induced by TPA treatment of P þ cells (Figure 2b ). Of this limited subset of six genes that were TPA inducible and suppressed by TAM67, three were transcription factors: c-Jun, HMGA1 and transcription factor IIb (TFIIb); one a translation initiation factor (eIF4A); one an early regulator of the NF-kB signaling pathway (IkBa); and one an EST with coding similarities to a mouse caveolar protein (Riken cDNA 1200011A11). Figure 1 Expression of dominant-negative c-Jun (TAM67) lowers AP-1-dependent transcription in P þ cells. In P þ cells, 24 h TPA (10 ng/ml) treatment induced AP-1 activity 2.5-fold (Po0.001, compared to DMSO control in P þ ) as measured by activation of a transfected 4 Â AP-1-luciferase promoter-reporter. Expression of TAM67 in P þ cells (P þ /TAM67) significantly lowered basal (po0.01, (a) compared to DMSO control in P þ ) and TPAinduced (Po0.001) AP-1 transactivation activity (P-values: **Ào0.01, ***Ào0.001; (a) -compared to DMSO control in P þ ; (b) -TAM67 þ TPA compared to TPA only in P þ ) Figure 2 Expression of dominant-negative c-Jun (TAM67) downregulates a limited subset of genes. A 2700 gene microarray was used to query comparative gene expression in P þ cells (P þ ) and P þ cells expressing TAM67 (P þ /TAM67) that were induced for AP-1 transactivation by TPA treatment for 6 or 18 h. (a) Genes showing 4twofold downregulation at one or both time points. Direct comparison of expression by paired hybridization to microarray of cDNA from P þ and P þ /TAM67 each treated with TPA (10 ng/ml) for 6 or 18 h (bars represent fold suppression as inverse ratio of TPAÀTAM67/TPA þ TAM67). The downregulated genes consist of those coding for three transcription factors (c-Jun, TFIIb and HMGA1), a translation initiation factor (eIF4A), an inhibitor of the NF-kB (IkBa) and an EST (RIKEN cDNA 1200011A11) that has coding similarity with a murine caveolar protein. Thus, this expression profiling identified a limited subset of genes that were downregulated by TAM67 expression concurrent with its blocking of TPA-induced AP-1 and tumor promotion.
In P þ cells, tumor promoter-induced expression of c-Jun and HMGA1 protein is inhibited by dominant-negative c-JUN (TAM67)
To ascertain whether microarray expression profiling was predictive of protein expression, we determined the protein levels of c-Jun and HMGA1 under parallel conditions. Both proteins are differentially expressed in JB6 transformation response variants. Expression of cJun is necessary to drive transformation of P þ cells, but not sufficient to convert transformation-resistant PÀ cells to a transformation-sensitive phenotype (Watts et al., 1995) . TPA-induced HMGA1 protein expression occurs in P þ but not PÀ cells, with peak expression between 12 and 24 h of induction (Cmarik et al., 1998) . The basal and TPA-induced expression of HMGA1 protein was downregulated by TAM67 in P þ cells ( Figure 3a ). In P þ /TAM67 cells, HMGA1 expression was absent without induction and low with induction at 24 h of TPA treatment. In the case of c-Jun, significant induction of protein expression occurred and c-Jun was present in the nucleus within 6 h of treatment in P þ cells. TAM67 had no effect on basal c-Jun protein levels, but significantly blocked the induction by TPA ( Figure 3b ).
TPA induction of HMGA1 is mediated through ERK-AP-1 activation
To further confirm that AP-1 activation is required for induction of HMGA1, we carried out an HMGA1 promoter-reporter assay with the AP-1 inhibitor TAM67 and an electrophoretic mobility shift assay (EMSA) with the AP-1-response element found in the mouse HMGA1 promoter. We also blocked the MAPK pathway to inhibit AP-1 induction by TPA. Extensive study of the human HMGA1 promoter has demonstrated TRE (AP-1) and TRE-like sites, transcriptional induction by TPA treatment and binding of AP-1 (Jun/ Fos) proteins (Friedmann et al., 1993; Ogram and Reeves, 1995) . The murine HMGA1a promoter also contains similar TRE and TRE-like sites (Pedulla et al., 2001) and TPA induces HMGA1a RNA expression in the P þ cells (Cmarik et al., 1998) . Using a mouse HMGA1 promoter-reporter construct (-1895HMGA1-GH containing B4.6 kb of the promoter region fused to a growth hormone reporter) (Wood et al., 2000b) transiently transfected into the P þ cells, we found that TPA induced transcription from the HMGA1 promoter (2.0 Â , Po0.001) and this induction was blocked by coexpression of TAM67 (0.46 Â , Po0.001) ( Figure 4a ). As previously reported (Wood et al., 2000b) , an HMGA1 promoter-reporter construct with a Myc mutation (-1895HMGA1-MM-GH) has less activity than the wild-type HMGA1 promoter, suggesting that the Myc site is important. The promoter construct with the Myc mutation, however, remains inducible by TPA (1.7 Â , Po0.05; Figure 4a ), indicating that TPA-inducible proteins regulate HMGA1 and can do so through a non-Myc site. When coexpressed with TAM67, the c-Myc mutant promoter was suppressed both for basal (0.56 Â 0.05) and TPA-induced (0.24 Â , Po0.01) response (Figure 4a) . Thus, the TAM-sensitive sites are present in the wild-type and in the myc-site mutant promoter, both of which share AP-1 sites. EMSA with nuclear extracts from TPA-treated (10 ng/ml, 3 h) P þ cells and a 30-mer oligonucleotide (À949 to -920 with respect to the first nucleotide of exon 1 as þ 1) encompassing the AP-1-binding site (À937 to -932; (Pedulla et al., 2001) ) in the murine HMGA1a promoter showed that FRA-1, Fra-2, JunB and JunD components of the AP-1 transcription factor bind to the promoter element (Figure 4b ). There was no binding by c-Jun and c-Fos. To further test whether TPA-induced ERK and AP-1 activation played a role in HMGA1 induction, we treated P þ cells with TPA in the presence and absence of the MAP kinase kinase (MEK-1/2) inhibitor U1026. While TPA induced HMGA1a protein expression significantly, pretreatment with U1026 completely inhibited HMGA1a expression (Figure 7a ). Thus, TPA-activated transcription from the HMGA1 promoter occurs in an ERK/AP-1-dependent manner that is inhibited by TAM67 expression.
Antisense HMGA1 inhibits tumor promoter-induced transformation response in P þ cells To determine whether HMGA1 protein expression is required for transformation of P þ cells, we inhibited HMGA1 expression in P þ cells by transfection of an antisense-HMGA1 construct. Previous studies have shown that expression of a full-length antisense cDNA construct (pRcCMVIGMH) reduces the endogenous levels of HMGA1 protein ). The construct is specific for HMGA1, with no effect on HMGA2 expression (data not shown). This HMGA1 antisense construct was transfected into P þ cells and single cell clones were selected by G418 treatment. Of 11 G418-resistant clones tested for HMGA1 protein expression, three clones (ash1, ash2, ash3) showed a consistent decrease in TPA-induced HMGA1 protein levels ( Figure 5a ). As reported before (Cmarik et al., 1998) , while basal HMGA1 protein levels were low or undetectable in PÀ and P þ cells, upon treatment with TPA there was substantial induction in P þ but not in PÀ cells. In P þ cells transfected with the vector backbone (v2, Figure 5a ), the HMGA1 expression pattern was similar to the parental P þ clone. Among the three antisense-HMGA1 clones, ash2 had a higher basal HMGA1 level than the other two clones. On induction with TPA, HMGA1 protein level ranged from 20 to 30% of the vector controls with ash1 and ash2 showing lower levels than ash3.
In the anchorage-independent transformation assay (Figure 5b ), the P þ and v2 cell lines demonstrated significant induction of colony formation with TPA treatment (B5-fold for both). For the clone ash1, both basal and induced level of colony formation was reduced significantly (Po0.05 and o0.01, respectively). In the case of ash2 and ash3, the TPA-induced colony formation was significantly inhibited (Po0.01 for both). The two clones most inhibited for induced Figure 4 AP-1 proteins bind to the HMGA1 promoter, transcription from which is sensitive to TAM67. (a) TPA induction of transcription from the HMGA1 promoter is blocked by dominantnegative c-Jun (TAM67). In P þ cells, TPA treatment (10 ng/ml, 24 h) induced transcription from the -1895 HMGA1-GH promoter reporter and this induction was inhibited by TAM67. TPA induced the c-myc site-mutated promoter-reporter (-1895 HMGA1-mm-GH), and both basal and induced levels were inhibited by TAM67 coexpression. (b) Specific AP-1 proteins bind to the AP-1 site on the HMGA1 promoter. EMSA with nuclear extract from TPA-treated (10 ng/ml, 3 h) P þ cells incubated with a 35-mer double-stranded oligonucleotide encompassing the AP-1 site and no other identified transcription factor binding sites from the HMGA1 promoter (control -lanes 1, 3; TPA treated -lanes 2, 4, 5-10). The mobility shift in lane 2 was inhibited when a point mutation was introduced into the AP-1 binding site (lane 4). Lanes 5, 6 and 8 show supershift and lane 9 shows blocked shift when oligonucleotide-nuclear extract mix is incubated with the respective antibodies The PÀ cells were cotransfected with HA-HMG-I or Y and Tet-on or Tet-off constructs and selected with G418 treatment. The clones were maintained with the transgene off during regular culture (Dox added for the Tet-off system, no Dox for the Tet-on system). Of 26 clones selected, four were reproducibly induced for expression of the transgene as detected by immunoprecipitation with the anti-HA antibody and subsequent Western probed with anti-HMGA polyclonal antibody. The four clones identified were Ioff-6, Yoff-1, Ion-3 and Yon-2, with the Tet-off clones induced in the absence of Dox and the Tet-on clones induced in the presence of Dox (Figure 6a) .
The two HMGA1a-expressing and the two HMGA1b-expressing clones were assayed for anchorage-independent transformation in response to TPA, comparing colony formation in the same clones with the HMGA1 proteins induced or not (Figure 6b ). In the P þ cell line used as positive control, there was a significant induction of colony formation by TPA treatment (420-fold, Po0.01). The use of Dox did not alter the response, except to slightly increase the absolute values. The PÀ transfectants all showed some increase in basal anchorage-independent colony formation independently of HMGA1 induction (gray bars). Of the four clones, none showed a gain of transformation response to TPA upon induction of HMGA1 expression (compare þ HMGA1 induction, -or þ TPA). Three of the four, I-on-3 and both Y clones appeared to show 1.5-to twofold increases in colony yield upon expression of HMGA1 in the absence of TPA (compare without TPA, À or þ HMGA1 induction, gray bars), but only one (Y-off-1, Po0.05) of the increases was a statistically significant gain in transformed phenotype. These results indicate that the expression of either the HMGA1a or HMGA1b proteins in PÀ cells is insufficient to render them sensitive to tumor promoter-induced transformation. HMGA1a or b expression is also insufficient to consistently produce in PÀ cells a gain of transformed phenotype. 
HMGA1 is one of multiple transformation-related factors that act downstream of critical ERK signaling
Since HMGA1 overexpression failed to sensitize or induce transformation in ERK-deficient PÀ cells, we asked whether in addition to HMGA1, other factors required for transformation of P þ cells act cooperatively downstream of ERK to permit transformation. Previous studies have shown that activated ERK levels are critical for the transformation of P þ cells, and the lack of ERK in PÀ cells prevents transformation . We therefore blocked TPA-induced ERK activation in P þ cells with a MEK-1/2 inhibitor (Figure 7a) , and determined the protein expression of HMGA1 and two other TPA-induced, AP-1-dependent transformation relevant genes, osteopontin and cyclin D1. Osteopontin is TPA inducible in P þ cells and its expression is required for transformation (Craig et al., 1989; Chang et al., 2003) . Cyclin D1 plays an important mechanistic role in mouse skin tumor promotion and is TPA inducible in P þ cells (Robles and Conti, 1995; Eto, 1998) . While TPA induced the expression of all three proteins, blocking ERK activation by the MEK inhibitor U1026 significantly reduced expression of HMGA1, osteopontin and cyclin D1 (Figure 7b) . Thus, expression of other ERKdependent proteins together with HMGA1 would be needed to rescue the transformation response in ERK-deficient PÀ cells.
Discussion
These results demonstrate that it is possible to identify a small subset of AP-1-regulated genes targeted by a dominant-negative c-Jun (TAM67) that play a critical role in epithelial cell tumor promotion. We provide evidence that one of the identified genes, HMGA1, is necessary, but not sufficient, to drive the transformation response. The expression of the transactivation domain-deleted dominant-negative c-Jun (TAM67) in the transformation-sensitive P þ cells facilitated our identification of AP-1-regulated genes that are suppressed during inhibition of transformation by TAM67. Of this small subset of six genes, three were transcription factors (c-Jun, Hmga1 and TFIIb), one a translation initiation factor (eIF4A), one an NF-kB pathway regulator (IkBa) and an EST with coding sequence similar to caveolar proteins (Riken cDNA 1200011A11). TPA-induction of the architectural transcription factor HMGA1 expression requires ERK/AP-1 activation. HMGA1 is a functionally significant target of TAM67 because blocking HMGA1 expression in transformation-sensitive P þ cells with an antisense construct blocked tumor promoter-induced transformation response. Induced overexpression of either HMGA1a or HMGA1b, the two proteins resulting from alternatively spliced HMGA1 mRNA, in the transformation-resistant PÀ cells was insufficient to confer transformation sensitivity or transformed phenotype.
Previous studies have shown that the transactivation domain-deleted c-Jun mutant (TAM67) is capable of blocking AP-1 transactivation function and tumor promotion concurrently, both in vitro (Dong et al., 1994) and in vivo (Young et al., 1999) . The in vivo studies using K14-TAM67 transgenic mice demonstrated that expression of TAM67 in the skin epithelial cells selectively inhibited tumorigenesis during two-stage carcinogenesis (DMBA initiation followed by TPA promotion), without affecting cell proliferation or TPA-induced hyperplasia. This indicated that a selected subset of AP-1-regulated genes that played a critical role in tumor promotion was the target of downregulation by TAM67. Therefore, differential expression profiling, in parallel with inhibition by TAM67 of TPA-induced transformation, was expected to identify a limited set of AP-1-regulated genes that played a critical role in tumor promotion. The microarray results identified six such genes whose expression was upregulated by TPA and downregulated in the presence of TAM67.
Of the six identified genes, the role of the c-Jun gene and c-Jun protein in skin tumorigenesis and other skin pathology in response to various stimuli (e.g. stress, cytokines, reactive oxygen species, UVB, activated Ras, HPV 16/18) is well documented (reviewed in Angel et al., 2001) . Like other AP-1 proteins, c-Jun not only dimerizes with Jun and Fos proteins but also interacts with numerous other transcription regulators like ATF, p65 subunit of NF-kB, CBP/p300 (CRE-binding-protein binding protein), SMAD-3 and -4, retinoblastoma Figure 7 Blocking TPA-induced ERK-1/2 activation inhibits expression of transformation-relevant proteins HMGA1, osteopontin and cyclin D1. (a) MEK inhibitor U1026 blocks phosphorylation of ERK-1/2. P þ cells were pretreated with U1026 (20 mM, 30 min) and then with TPA (10 ng/ml, 6 h). Western blot of total cell lysate was probed with phospho-ERK, total ERK and b-actin antibodies. (b) Pretreatment of P þ cells with the MEK inhibitor U1026 blocks TPA-induced expression of HMGA1, osteopontin and cyclin D1 protein. P þ cells were pretreated with U1026 (20 mM, 30 min) and then with TPA (10 ng/ml; 6 h for osteopontin and cyclin D1, 24 h for HMGA1). Western blot of total cell lysate was probed with osteopontin, cyclin D1 and b-actin antibodies. For HMGA1, perchloric acid-extracted protein was used for Western blot and probed with anti-HMGA1 antiserum HMGA1 is necessary for epithelial transformation A Dhar et al protein (Rb) and others (reviewed in Chinenov and Kerppola, 2001 ). Interestingly, c-Jun also interacts with the product of another target gene identified in this study, namely the HMGA1 protein (Du et al., 1993) . The HMGA1 protein is closely associated with multiple human malignancies and is known to contribute to tumor progression through invasion and metastasis (discussed below). This architectural transcription factor controls gene transcription in association with a number of other transcription factors, including AP-1 and NF-kB (Du et al., 1993; Lewis et al., 1994; Chin et al., 1998; Himes et al., 2000; Bouallaga et al., 2003) . The IkBa protein (also shown to be a TAM67 target, Young MR et al unpublished data) is associated with control of activation and nuclear localization of the NF-kB transcription factor (Whiteside and Israel, 1997).
The NF-kB group of transcription factors is important in tumor promotion and progression in the mouse skin, the JB6 and other models (Sovak et al., 1997; Budunova et al., 1999; Li et al., 2000; Hsu et al., 2001) . The translation initiation factor eIF4A interacts with Pdcd4 (programmed cell death 4) protein, an inhibitor of translation that acts as a transformation suppressor and is expressed in PÀ, but not in P þ cells (Cmarik et al., 1999; Yang et al., 2001; Yang et al., 2002; Yang et al., 2003) . The role of the other two gene products -TFIIb and RIKEN cDNA 1200011A11 -in tumor promotion is not as yet defined. Elevated expression of HMGA1 protein has been associated with multiple human tumors (Ram et al., 1993; Tamimi et al., 1993; Abe et al., 1999) . Overexpression of HMGA1b contributes to maintaining tumor phenotype and to epithelial-mesenchymal transition in the human mammary epithelial carcinoma cell line MCF-7 . Transformation of rat thyroid cells by v-ras-Ki requires expression of HMGA1 (Berlingieri et al., 2002) . HMGA1 has been shown to drive transformation in rat fibroblasts and lymphoid cells (Wood et al., 2000a, b) . The present study is unique in addressing the question of whether HMGA1a or HMGA1b is necessary or sufficient for the process of epithelial tumor promotion. The human HMGA1 promoter is regulated by AP-1 (Ogram and Reeves, 1995) and mouse HMGA1 mRNA is TPA inducible differentially in tumor promotion-sensitive P þ and -resistant PÀ murine epidermal cell lines (Cmarik et al., 1998) . HMGA1b, but not HMGA1a, is induced by TPA in P þ cells while neither is induced in PÀ cells (Cmarik et al, 1998) .
Our results show that HMGA1 induction by TPA requires activation of ERK-1/2, which itself is a critical component of TPA-induced transformation response. Moreover, EMSA and promoter-reporter studies with the HMGA1 promoter element show that AP-1 transcription factors bind to the AP-1 site in the promoter and the TPA induction of the HMGA1 promoter is blocked by TAM67. Thus, TPA induces HMGA1 in an ERK-1,2/AP-1-dependent manner. The present study establishes that HMGA1 induction is necessary, but not sufficient for tumor promoterinduced transformation of initiated cells. Although neither HMGA1a nor b suffices to render resistant cells sensitive to transformation, the possibility exists that the transformation requirement may apply only to HMGA1b.
In addition to HMGA1, what other factor/s are needed for transformation? The P þ and PÀ cells show differential expression of a number of proteins, some of which have been identified as critical for the transformation response (reviewed in Dhar et al., 2002) . One such critical protein is the extracellular signal-regulated kinase 1,2 (ERK-1,2) of the MAPK pathway . Elevating ERK-1,2 levels in PÀ cells by transfecting with ERK1,2 expression vectors produced a gain of sensitivity to TPA-and EGF-induced AP-1 activation and transformation. Conversely, blocking ERK-1,2 activity in P þ cells renders them resistant to TPA-induced transformation (Watts et al., 1998) . Therefore, ERK is necessary and sufficient to drive the AP-1 activation and transformation responses in the JB6 PÀ cells. The current findings establish that in addition to HMGA1, expression of other transformation-required proteins (osteopontin, cyclin D1) is also dependent on ERK-1,2 activation. The observation that HMGA1 is not sufficient by itself to drive transformation in PÀ cells indicates that it cannot substitute for ERK 1,2 and excludes the possibility that signaling to transformation converges through HMGA1. From this we can conclude that HMGA1 is one required, but not the only required, AP-1 target gene that contributes to the process of tumor promotion (Figure 8 ). HMGA1 might thus represent a suitable molecular target for cancer prevention. Figure 8 HMGA1 is one of a limited number of AP-1-regulated TAM67 target genes that contributes to the process of neoplastic transformation. Tumor promoter-induced AP-1 activation leads to transcriptional upregulation of a number of genes, a subset of which is functionally significant and targeted by TAM67 when it blocks transformation. HMGA1 is a functionally significant AP-1 and TAM67 target that is necessary but not sufficient for the transformation response. AP-1-dependent and AP-1-independent events converge to produce transformation
Materials and methods

Cell culture
Mouse epidermal JB6 cells have been described previously and were grown according to protocol (Bernstein and Colburn, 1989) . Briefly, JB6 P þ cells were cultured in EMEM (BioWhitaker, Frederick, MD, USA) supplemented with 4% fetal bovine serum (FBS), 2 mM L-glutamine and 25 mg/ml gentamycin (Invitrogen, Carlsbad, CA, USA) at 361C in a humidified atmosphere containing 5% CO 2 . TPA (Alexis Biochemicals, Lauzanne, Switzerland) was dissolved in DMSO (Sigma, St Louis, MO, USA) at 100 mg/ml and, after further dilution in medium, used at a final concentration of 10 ng/ml. TNFa (PeproTech Inc., Rocky Hill, NJ, USA) was dissolved in water at 10 mg/ml and used at a final concentration of 10 ng/ml.
The TAM67-expressing transgenic P þ cell line (M3C) and the vector-transfected control P þ cell line (N1E) were used for array, transactivation and protein expression studies. Construction of these stable transfected cell lines and their characterization is described in Dong et al. (1994) . The cell lines were maintained as P þ cells, except that they were selected with G418 (250 mg/ml; GIBCO-BRL, Gaithersburg, MD, USA) treatment every 4 weeks. They were assayed for transformation phenotype and AP-1 transactivation function every 8 weeks.
Promoter-reporter assays
For the AP-1 promoter-reporter, we used a 4x TRE sequence from the GCN4 promoter fused to the luciferase reporter (4xAP-1-luciferase, previously described in Dong et al., 1995) . The N1E (pMM vector) and M3C (pMM-TAM67) cells were plated at 2 Â 10 4 cells/well in 24-well culture plates. The cells were transiently cotransfected with the 4xAP1-luciferase (0.4 mg/well) and renella-luciferase construct (0.02 mg/well) as control, using the FuGENE6 system as per the manufacturer's protocol (Roche Applied Sciences, Indianapolis, IN, USA). The cells were serum starved (0.2% FBS in medium) for 24 h before treatment. Subsequently, they were treated either with TPA (10 ng/ml) or DMSO for 24 h. The cells were lysed in passive lysis buffer and luciferase activity in lysate was measured according to the manufacturer's protocol (Promega Corp., Madison, WI, USA). Luciferase activity was read with a Dynex luminometer (DYNEX Technologies, Chantilly, VA, USA).
For the murine HMGA1 promoter reporter assay, we used the -1895 HMGA1-GH and -1895 HMGA1-myc mutant-GH promoter reporters that have been described before (Wood et al., 2000b) . The P þ cells were plated, transfected and treated as described above. Growth hormone (GH) was assayed in culture supernatant at a dilution of 1 : 5 using a GH ELISA kit as per the manufacturer's protocol (Roche Biochemicals, Indianapolis, IN, USA).
Analysis of gene expression with cDNA microarray
The N1E (P þ /vector) and M3C (P þ /TAM67) cells were plated and grown to 70-80% confluence in T75 tissue culture flasks, serum starved for 24 h (culture medium with 0.2% FBS), then treated with either DMSO (0.01%) or TPA (10 ng/ml) for 6 or 18 h. After removing culture medium at appropriate time points, the cells were lysed in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and RNA extracted as per the manufacturer's protocol. Paired cDNA samples, labeled by cy3-and cy5-dUTP incorporation during reverse transcription, were hybridized to 2.7 k NCI mouse oncochip cDNA array as per NCI in-house protocol (available at http://mach1.nci.nih.gov/). Paired sets consisted of N1E þ TPA/N1E þ DMSO (genes induced by TPA) or M3C þ TPA/N1E þ TPA (TAM67 inhibition of TPA-induced genes) from same time point (See Figure 2) . After overnight hybridization and wash, slides were scanned and fluorescent images were captured using Genepix 4000 (Axon Instruments, Inc., Foster City, CA, USA). Genepix 3.0 software was used to create the image and preliminary data file that were then analysed by NCI Center for Information Technology (CIT) programs and database. Spots with signal to background ratio of 42 were further analysed for up-or downregulation of genes. Results shown are the average of two independent experiments for treatment at each time point.
EMSA
JB6 cells were serum starved (0.2% FBS) for 24 h followed by TPA (10 ng/ml) stimulation for another 3 h. Nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents as per the manufacturer's protocol (Pierce Biotechnology, Inc., Rockford, IL, USA). A Gel Shift Assay System from Promega (Madison, WI, USA) was used for EMSA and all the experimental procedures were carried out according to the protocol provided. In total, 2 mg of the nuclear extracts was used for each reaction. The AP-1 antibodies used for supershift assay including anti-fra-1, anti-fra-2, anti-c-jun, anti-junD and anti-c-fos were purchased from Santa Cruz. Double-stranded oligonucleotides from HMGA1a regulatory region containing AP-1 consensus sequence 5 0 ggaacagagttatgagtcacagtcgtgtgt3 0 and a point mutation in the AP-1 site 5 0 ggaacagagttatgagttgcagtcgtgtgt3 0 were purchased from Integrated DNA Technologies (Coralville, IA, USA). The protein-DNA complexes were resolved on a 6% Retardation gel (Invitrogen) and visualized by autoradiograph.
Selection and maintenance of HMGA1 antisense-expressing and transgenic clones
Construction of the HMGA1 antisense expression vector pRcCMVIGMH (Himes et al., 1996) , and the HA-tagged HMG-I (or HMGA1a) and HMG-Y (or HMGA1b) ) have been described previously. All HMGA1 constructs were of human origin. Transfection of all constructs was carried out using FuGENE 6 (Roche Applied Bioscience, Indianapolis, IN, USA) and the manufacturer's protocol. Transfected P þ cells were selected by resistance to G418 treatment (300 mg/ml) and cloned by limiting dilution. Of the 21 pRcCMVIGMH clones selected, seven showed various degrees of suppression of HMGA1 expression on Western blots. Three clones with varying HMGA1 expression (ash1, ash2, ash3) were used in the study. The cells were grown under similar conditions as parental P þ cells, and selected for G418 resistance every 6-8 weeks.
The HA-tagged human HMGA1 sense expression constructs -HA-HMG-I and HA-HMG-Y -were cloned into the pTRE expression vector (Clontech, Palo Alto, CA, USA) as previously described . The HMGA1 transgenic clones were derived by cotransfection of either HA-HMG-I or HA-HMG-Y and either of the regulator plasmids Tet-off or Tet-on (Clontech, Palo Alto, CA, USA) into the JB6 PÀ cells. Transfected cell selection with G418 (100 ng/ml) was carried out and clones were obtained by limiting dilution. The clones were maintained as JB6 cells, except that regular FBS was substituted by Tet-free FBS 
Acid extraction of HMGA1 proteins and Western blot analysis
For all Western blot purposes, P þ cells were grown to B70% confluence in 150 mm tissue culture dishes, serum starved for 24 h (0.2% FBS in EMEM) and then treated with TPA (10 ng/ml) or DMSO for the required time. The HMGA1 proteins were acid extracted from whole-cell pellets with 5% perchloric acid as described previously (Reeves and Nissen, 1999) . The acid-extracted proteins (other HMG proteins, histone H1 and a few others) were separated by SDS-PAGE on a 4-12% Tris-Bis minigel (Invitrogen, Carlsbad, CA, USA). The proteins were transferred to nitrocellulose membrane (Schleicher and Schuell) by electrophoresis. Detection of HMGA1 proteins on the membrane was carried out using a rabbit polyclonal anti-HMGA1 antibody (MR-19, previously described in Reeves and Nissen, 1999) and an enhanced chemiluminescence detection procedure using ECL chemiluminescence kit (Amersham Biosciences, Little Chalfont, Buckinghamshire, England). The polyclonal anti-HMGA1 antibody does not bind HMGA2 protein (Adair J and Reeves RR, Supplemental Figure 1 ).
For Western blots to detect nuclear c-Jun levels, nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents as per the manufacturer's protocol (Pierce Biotechnology, Inc., Rockford, IL, USA). For detection of osteopontin and cyclin D1 proteins, whole-cell lysate were prepared by lysing cell pellets in 200 ml lysis buffer (250 mM sodium chloride, 0.1% NP-40, 20 mM sodium di-hydrogen phosphate, 30 mM Na-pyrophosphate, 5 mM EDTA, 10 mM sodium fluoride, pH 7.0) with protease inhibitors and collecting supernatant after centrifugation at 2500 g for 5 min.
Detection of transgenic HA-tagged HMGA1a and HMGA1b by immunoprecipitation and Western blot analysis
Cells grown to B70% confluency in 150 mm culture dishes were treated as required. Immunoprecipitation from cell lysates were carried out as described in Reeves et al. (2001) with two modifications. The IP buffer composition (Tris-HCl pH 7.5 50 mM, NaCl 150 mM, EGTA 1 mM, NP-40 1%, glycerol 10%; and 1 Â protease inhibitor cocktail from Roche Diagnostics) was different. The anti-HA antibody used for IP (12CA5) was obtained from Roche Applied Sciences (Indianapolis, IN, USA) . Separation of protein by SDS-PAGE and detection by Western blot using the anti-HMGA antibody was as detailed above.
Anchorage-independent growth assay in soft agar Soft-agar assays for transformation were carried out as described previously (Li et al., 1997) . Using a 60-mm tissue culture dish, the bottom was layered with 7 ml of 0.5% agar in EMEM (10% FBS) and let to solidify. A total of 10 000 JB6 cells were suspended in 1.5 ml of 0.33% agar in EMEM (10% FBS), layered on top and incubated at 361C for 14 days. Both layers of agar were supplemented with TPA (10 ng/ml) or DMSO. For the HA-HMG-I or Y PÀ transgenic cells, a similar assay was carried out, except without or with Dox (10 ng/ml) as required for induction of transgenic HA-HMG-I or Y. The formed colonies were counted by an automated image analysis system (Image Pro-Plus software, Media Cybernetics, Silver Spring, MD, USA). Transformation response is expressed as number of colonies formed per 10 000 cells per 60-mm dish (mean7s.d. of four dishes per treatment).
Statistical analysis
Statistical significance of the differences between groups in each assay was determined by two-tailed Student's t-test with unequal variance.
